Cell-free DNA (cfDNA) sequencing is the most widely used clinical liquid biopsy platform and has identified circulating tumor DNA content and AR genomic alterations as biomarkers that associate with ARPI resistance and poor survival (18). The gene discussed is AR; the disease is neoplasm.